We analysed the past 20 years of drug project history with the aim of understanding more about how the pharmaceutical industry has been performing with regard to therapeutic mechanisms and their ...
The prospect of targeting inflammation to treat residual cardiovascular risk using the monoclonal antibody canakinumab (Ilaris) appears to be slim to none in the wake of recent decisions from ...
Figure 1: Summary of data resources and mappings between them. Figure 2: Enrichment of target genes for drugs approved in the United States or the European Union. Figure 3: Overlap between drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results